title: [Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer].
abstract: A 75-year-old man with chronic renal failure was on maintenance hemodialysis.He was admitted to our hospital for advanced gastric cancer with multiple liver metastases (cStage IV).Three courses of tegafur-uracil (300 mg/day daily) plus docetaxel (20 mg/m², every 3 weeks) as first-line treatment and nine courses of tegafur-uracil (same dose) plus CPT-11 (64 mg/m², day 1, 15, every 4 weeks) were given without any complications.Docetaxel and CPT-11 were given on days between hemodialyses. No severe adverse effects of more than grade 3 were encountered. The standard regimens in our country for unresectable advanced gastric cancer are the S-1 single or S-1/CDDP combined chemotherapies that have already been evidenced in the JCOG 9912 and SPIRITS trial. However, no standard chemotherapy for patients on hemodialysis has been reported as yet.Therefore, doctors in charge must arrange an individualized regimen for each patient, considering metabolic characteristics of each anti-cancer agent.In this context, our case was considered to be very suggestive, and that is why we report it here in detail.
authors.affiliation: Division of Gastroenterology and Hepatology, Nagaoka Red Cross Hospital, Japan.
authors.forename: Tomofumi
authors.initials: T
authors.lastname: Miura
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Hosojima
authors.forename: Junichiro
authors.initials: J
authors.lastname: Nakamura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamada
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Nakazawa
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ozeki
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Miura
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yanagi
authors.forename: Hajime
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Toru
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077143:Docetaxel; D006801:Humans; D000077146:Irinotecan; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D009367:Neoplasm Staging; D010166:Palliative Care; D006435:Renal Dialysis; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D043823:Taxoids; D005641:Tegafur; D000077143:Docetaxel; D000077146:Irinotecan; D002166:Camptothecin